Keliximab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Keliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (primate/human)
TargetCD4
Clinical data
Routes of
administration
intravenous
ATC code
  • none
Identifiers
CAS Number
  • 174722-30-6 ☒N
ChemSpider
  • none
 ☒NcheckY (what is this?)  (verify)

Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]

References[edit]

  1. ^ Kon OM, Sihra BS, Compton CH, Leonard TB, Kay AB, Barnes NC (October 1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet. 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587. S2CID 29868851.
  2. ^ "Proposed INN List" (PDF). WHO Drug Information. 10 (4). 1996.